SCHLEIFER LEONARD S 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
SCHLEIFER LEONARD S
DirectorCEO and President10% Owner
Transactions
- Exercise/Conversion
Common Stock
2025-12-31+28,570→ 243,093 total - Tax Payment
Common Stock
2025-12-31$772.09/sh−28,570$22,058,611→ 214,523 total - Exercise/Conversion
2020 Performance Stock Units
2025-12-31−28,570→ 595,077 total→ Common Stock (28,570 underlying)
Holdings
- 127,484(indirect: By 2024 GRAT)
Common Stock
- 300,000(indirect: By 2025 GRAT)
Common Stock
- 5,989(indirect: By 401(k))
Common Stock
- 39,985(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of Company stock. These PSUs were earned during the applicable five-year performance period and vested on December 31, 2025 but remain subject to a mandatory holding period of three years after vesting, which ends early upon the reporting person's death or disability or a change in control of the Company.